|Bid||5,400.00 x 100|
|Ask||0.00 x 100|
|Day's range||5,420.00 - 5,482.97|
|52-week range||4,766.00 - 8,700.00|
|Beta (5Y monthly)||0.39|
|PE ratio (TTM)||13.89|
|Earnings date||19 Oct 2021 - 25 Oct 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
CAMBRIDGE, Mass., October 19, 2021--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced their plan to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for zuranolone, an investigational two-week, once-daily therapeutic in the second half of 2022. The planned initial submission package will seek approval of zuranolone for the treatment of major depressive disorder (MDD) and an additional filing for postpartum depression (PPD) is
Investor focus is likely to be on sales of new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports third-quarter earnings.
Biogen's (BIIB) phase III study evaluating tofersen for ALS with SOD1 mutation fails to meet the primary endpoint of the study. However, the study shows signs of reduced disease progression with tofersen.